Follow POL on Twitter David Walk utterly shreds an appalling piece of agitprop masquerading as science in the New England Journal of Medicine. One hopes Walk doesn't restrict himself to the blog post, but also writes a letter to the editor.
"Whistle-Blowers' Experiences in Fraud Litigation against Pharmaceutical Companies"
Related Entries:
- An employee's revenge
- Roundup, July 18
- Around the web, March 1
- Breaking: N.D. Ohio court finds false marking statute unconstitutional
- "New Breed of Patent Claim Bedevils Product Makers"
- Trial Lawyers, Inc.: K Street -- Federal Government Relations (I)
- Hanging out in Maui with the litigation industry
- In California, advice on more remunerative litigation
- Bounty-hunters' paradise?
- Examiner on whistleblower law
- "Obama signs bill amending False Claims Act"
- Northrop Grumman qui tam settlement
- Katrina whistleblower litigation, cont'd
- Preemption: Meanwhile, back at the convention
 |
| Isaac Gorodetski Project Manager, Center for Legal Policy at the Manhattan Institute igorodetski@manhattan-institute.org |
 |
| Laura Eyi Press Officer, Manhattan Institute leyi@manhattan-institute.org |
